The report provides a detailed analysis essential for establishing a cycrimine production plant. It encompasses all critical aspects necessary for cycrimine production, including the cost of cycrimine production, cycrimine plant cost, cycrimine production costs, and the overall cycrimine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a cycrimine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Cycrimine is a synthetic anticholinergic compound that is mainly used in the pharmaceutical field. It is primarily prescribed for the management of symptoms associated with Parkinson’s disease, where it helps reduce muscle stiffness and tremors. It works by blocking certain nerve signals in the brain to reduce muscle stiffness, shaking, and slow movements by blocking signals that overstimulate the muscles. It reduces the levels of acetylcholine to restore the normal dopamine-acetylcholine balance.
It is often included in treatment plans for patients who need added support when other therapies do not fully control these symptoms. It finds its main application in improving motor control and reducing rigidity in patients with movement disorders. It may also help ease uncontrolled muscle spasms that arise from long-term use of antipsychotic medicines. Moreover, it is also sometimes used to manage drug-induced extrapyramidal symptoms caused by certain antipsychotic medicines. It also finds its role in research for potential antiviral effects against certain flu viruses.
The market for cycrimine is primarily driven by its demand as a drug for the treatment of certain neurological conditions, which boosts its demand in the medical and healthcare sectors. Its application as a medication for the treatment and management of Parkinson's disease significantly promotes its demand in the medical and pharmaceutical industries. Its usage as a drug in improving motor control and reducing rigidity in patients with movement disorders further supports its demand in the healthcare industry.
Its demand in treating motor issues linked to Parkinson's and related conditions like dystonia for improving daily functioning and comfort in patients with neurological conditions also drives its market growth. The growing ageing population and the rising number of patients diagnosed with neurological disorders are also encouraging its usage across healthcare systems. Additionally, industrial cycrimine procurement is influenced by factors such as the availability and cost of active pharmaceutical ingredients, regulatory approvals, quality standards, and compliance with production guidelines. Advances in pharmaceutical production technologies, reliable supplier networks, and efficient distribution systems also play an important role in shaping the global procurement and supply of cycrimine.
Raw Material for Cycrimine Production
According to the cycrimine production plant project report, the major raw materials for cycrimine production include phenyl magnesium bromide, cyclohexyl β-(N-piperidyl)-ethyl ketone, hydrochloric acid, ammonium hydroxide, and ammonium chloride.
Production Process of Cycrimine
The extensive cycrimine production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of cycrimine begins with the preparation of phenyl magnesium bromide by reacting bromobenzene with magnesium in dry ether to form a Grignard reagent. This freshly prepared reagent is then slowly added to cyclohexyl β-(N-piperidyl)-ethyl ketone under controlled low temperature conditions to facilitate Grignard addition. The reaction mixture is brought to room temperature and then refluxed to complete the transformation, followed by quenching with ice and hydrochloric acid to decompose the reaction complex. After basification with ammonium hydroxide and addition of ammonium chloride, the organic layer is separated, dried, and the solvent removed. Finally, purification of the resulting crude base by distillation under reduced pressure, followed by recrystallisation from methanol, gives cycrimine as the desired product.
Cycrimine is a central anticholinergic agent belonging to the class of piperidines, and it acts as a muscarinic acetylcholine receptor M1 antagonist. It appears as an off-white to pale yellow solid. The molecular formula of the compound is C19H29NO, and its molar mass is 287.44 g/mol. Its density is approximately 1.057 g/cm³, and it is slightly soluble in chloroform and methanol but soluble in ethyl acetate. Additionally, the compound has a melting point of 112-113 degrees Celsius and a boiling point of 125–135 degrees Celsius. The compound is marketed under the trade name Pagitane. The compound should be stored at -20 degrees Celsius under an inert atmosphere. It is recommended to wear protective clothing while handling the compound. Extended exposure to this substance may cause adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and central nervous system disturbances, including hallucinations, particularly in elderly patients.